The Russian Direct Investment Fund (RDIF), an investor of the Russian Covid-19 vaccine Sputnik V, introduced on Sunday that the vaccine demonstrated a better or equal tolerability profile among the many 60 plus age group in San Marino throughout the inoculation marketing campaign within the nation.
An official launch from the RDIF stated that the outcomes are based mostly on a nationwide research performed, between March four and April 8, amongst people in San Marino who acquired one or each doses of Sputnik V. A descriptive evaluation was later performed to quantify the incidence of antagonistic occasions following immunisation on each events.
“Our results, albeit preliminary, suggest that Sputnik V has a high tolerability profile in the population aged ≥60 years in terms of short-term AEFIs. This preliminary analysis suggests a higher or equal tolerability profile of the Sputnik V vaccine in the 60+ age group, after both doses, as compared with other widely adopted Covid-19 vaccines,” stated the assertion.
The outcomes have been revealed in EClinicalMedicine, an open entry medical journal revealed by The Lancet.
“Our results also align with the findings of phase 1 and 2 previously conducted studies, then confirmed by phase 3 of the vaccine trial, in terms of overall safety and tolerability. No hospitalizations or deaths were reported. Nearly all reported AEFIs were mild or moderate and/or lasted less than 2 days,” the assertion added.
Sputnik V was the third vaccine to be granted an emergency use authorisation in India on April 12, 2021 after indigenously developed Covaxin and Covishield.
Follow us on Google News